Literature DB >> 31555537

Effect of epicardial application of amiodarone-releasing hydrogel on heart rate in an animal model.

Teymuraz N Kanametov1, Vladimir A Shvartz1, Natalia D Oltarzhevskaya1, Olga L Bockeria1.   

Abstract

BACKGROUND: The purpose of the experiment was to study the safety of local epicardial use of the hydrogel with amiodarone, as well as the influence of its different dosages on the heart rate of mongrel rabbits.
METHODS: The epicardial application of the hydrogel material with amiodarone was performed in 46 rabbits. Rabbits were divided into 5 groups: Group No. 1-dose of amiodarone in the hydrogel 1 mg, Group No. 2-dose 3 mg; Group No. 3-dose 6 mg; Group No. 4-hydrogel without amiodarone; Group No. 5-amiodarone intravenously, 60 mg.
RESULTS: The application of hydrogel with amiodarone is not accompanied by a systemic inflammatory reaction. In group No. 2, there was a significant reduction in the heart rate (before surgery: 158±16, after: 130±11, (P<0,001), without any disturbances to the conduction system of the heart functioning. With an increase in amiodarone concentration (Group No. 3), significant atrial and atrioventricular (AV) conduction defects (up to 70%) were noted; when the dosage of amiodarone (Group No. 1) was reduced, there was no influence on the heart rate reduction. The hydrogel without amiodarone has no effect on the conductive system.
CONCLUSIONS: The method of local epicardial delivery of amiodarone in the form of a hydrogel material is safe. The hydrogel with amiodarone is effective for the heart rate reduction (according to the experiment on animals), compared to the control group and the group with intravenous drug administration. The optimal dosage of amiodarone in the hydrogel is 3 mg.

Entities:  

Keywords:  Cardiosurgery; amiodarone-releasing hydrogel; biomarkers; heart rate; rabbits

Year:  2019        PMID: 31555537      PMCID: PMC6732076          DOI: 10.21037/cdt.2019.04.01

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  16 in total

1.  Distribution of amiodarone in heart tissues following intrapericardial administration.

Authors:  J T Darsinos; J N Karli; E C Samouilidou; B Krumbholz; A C Pistevos; G M Levis
Journal:  Int J Clin Pharmacol Ther       Date:  1999-06       Impact factor: 1.366

2.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Craig T January; Kenneth A Ellenbogen; James E Lowe; N A Mark Estes; Richard L Page; Michael D Ezekowitz; David J Slotwiner; Warren M Jackman; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Jean-Yves Le Heuzey; Harry J Crijns; James E Lowe; Anne B Curtis; S Bertil Olsson; Kenneth A Ellenbogen; Eric N Prystowsky; Jonathan L Halperin; Juan Luis Tamargo; G Neal Kay; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Judith S Hochman; Christopher E Buller; Frederick G Kushner; Mark A Creager; Erik Magnus Ohman; Steven M Ettinger; William G Stevenson; Robert A Guyton; Lynn G Tarkington; Jonathan L Halperin; Clyde W Yancy
Journal:  Circulation       Date:  2010-12-20       Impact factor: 29.690

Review 3.  Pharmacologic prophylaxis of postoperative atrial fibrillation in patients undergoing cardiac surgery: beyond beta-blockers.

Authors:  Estella M Davis; Kathleen A Packard; Daniel E Hilleman
Journal:  Pharmacotherapy       Date:  2010-07       Impact factor: 4.705

4.  Topical application of a biodegradable disc with amiodarone for atrial fibrillation.

Authors:  Takahide Takeda; Takeshi Shimamoto; Akira Marui; Naritatu Saito; Kyokun Uehara; Kenji Minakata; Senri Miwa; Naoki Nakajima; Tadashi Ikeda; Suong-Hyu Hyon; Ryuzo Sakata
Journal:  Ann Thorac Surg       Date:  2011-03       Impact factor: 4.330

Review 5.  Beyond the guidelines: new and novel agents for the prevention of atrial fibrillation after cardiothoracic surgery.

Authors:  Kurt Reinhart; William L Baker; Melanie Ley-Wah Siv
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-12-15       Impact factor: 2.457

6.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery.

Authors:  L Brent Mitchell
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

7.  Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy.

Authors:  Massimo Imazio; Antonio Brucato; Paolo Ferrazzi; Maria Elena Rovere; Anna Gandino; Roberto Cemin; Stefania Ferrua; Riccardo Belli; Silvia Maestroni; Caterina Simon; Edoardo Zingarelli; Alberto Barosi; Fabrizio Sansone; Davide Patrini; Ettore Vitali; Rita Trinchero; David H Spodick; Yehuda Adler
Journal:  Circulation       Date:  2011-11-16       Impact factor: 29.690

Review 8.  Prescribing amiodarone: an evidence-based review of clinical indications.

Authors:  Patricia Vassallo; Richard G Trohman
Journal:  JAMA       Date:  2007-09-19       Impact factor: 56.272

9.  The role of inflammation in atrial fibrillation following open heart surgery.

Authors:  S Canbaz; H Erbas; S Huseyin; E Duran
Journal:  J Int Med Res       Date:  2008 Sep-Oct       Impact factor: 1.671

10.  Inflammation as a risk factor for atrial fibrillation.

Authors:  Ronnier J Aviles; David O Martin; Carolyn Apperson-Hansen; Penny L Houghtaling; Pentti Rautaharju; Richard A Kronmal; Russell P Tracy; David R Van Wagoner; Bruce M Psaty; Michael S Lauer; Mina K Chung
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

View more
  1 in total

1.  Local Use of Hydrogel with Amiodarone in Cardiac Surgery: Experiment and Translation to the Clinic.

Authors:  Vladimir Shvartz; Teymuraz Kanametov; Maria Sokolskaya; Andrey Petrosyan; Tatyana Le; Olga Bockeria; Leo Bockeria
Journal:  Gels       Date:  2021-03-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.